HK
Therapeutic Areas
Pyxis Oncology Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Micvotabart pelidotin (MICVO) Monotherapy | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 2L+ | Phase 1 |
| Micvotabart pelidotin (MICVO) + KEYTRUDA® | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) - 1/2L+ | Phase 1 |
Leadership Team at Pyxis Oncology
TC
Thomas Civik
Interim Chief Executive Officer and Board Director
BB
Balu Balasubramanian
Interim Chief Technology Officer
MB
Michael Bui
SVP, Global Regulatory Affairs
CC
Chris Cohen
Head of Drug Safety and Pharmacovigilance
MC
Marsha Crochiere
Head of Translational Medicine and Research
TD
Tom Dorney
SVP, Strategy and Financial Planning
BF
Brian Freeman
Chief Program Officer
SH
Shui He
Head of Biometrics
TJ
Troy J. Huth
Head of Intellectual Property & Legal
AK
Alex Kane
SVP, Investor Relations & Capital Markets